Context Therapeutics Stock Performance

Relative Risk vs. Return Landscape

If you had invested $ 217.00 in Context Therapeutics on February 7, 2026 and sold it today, you would have earned $ 24.00 , a return of 11.06% over 90 days. Context Therapeutics is currently generating a 0.3097% daily expected return and carries 5.31% risk (volatility on return distribution) over a 90-day horizon. In relative terms, Context Therapeutics exhibits above-average volatility, exceeding roughly 53% of comparable stocks, and CNTX has trailed 94% of traded instruments in return over the 90-day horizon.This market-relative note looks at return potential and the amount of risk required to get it. It is intended to show how efficiently risk has translated into return over the selected horizon. Given a 90-day horizon, CNTX generates 5.71 times more return on investment than the market. However, CNTX is 5.71 times more volatile than its market benchmark. Its risk-adjusted efficiency stands at about 0.06% per unit of risk. Dow Jones Industrial is currently generating roughly -0.01% per unit of risk.

Target Price Odds to finish over Current Price

Given a 90-day horizon, Context Therapeutics has a beta of -0.12 suggesting that as returns on the benchmark increase, returns on Context Therapeutics tend to move in the opposite direction, though by a smaller magnitude. During a bear market, however, Context Therapeutics tends to outperform the market. Additionally, Context Therapeutics has an alpha of 0.1552, implying that it can generate a 0.1552 percent excess return over Dow Jones Industrial after adjusting for the inherent market risk (beta).

Predictive Modules for Context Therapeutics

Forecasting Context Therapeutics involves applying various models to estimate future stock price behavior. Despite uncertainty, systematic forecasting provides investors with structured context for evaluating Context Therapeutics. Comparing results across methods can improve accuracy, even in unpredictable stock markets.

Sentiment Range Low Sentiment High 0.12 2.43 7.74 Details

Intrinsic Valuation Low Intrinsic High 0.10 1.97 7.28 Details

Naive Forecast Low Next High 0.05 2.30 7.61 Details

Analyst Consensus Low Target High 5.46 6.00 6.66 Details

Context Therapeutics's financial and valuation profile is evaluated here relative to direct competitors. Context Therapeutics's multiples and operating metrics gain context when measured against direct competitors. Growth rates, profitability, and capital efficiency relative to peers frame Context Therapeutics' competitive position.

Primary Risk Indicators

Market volatility over the last 10-20 years has created both risk and opportunity across stock markets including Context Therapeutics. The pattern of corrections and recoveries in Context Therapeutics mirrors the broader stock market experience. Implementing a hedging strategy and tracking Context Therapeutics' volatility limits the impact of adverse moves.

Investor Alerts and Insights

Real-time alerts for Context Therapeutics track important stock developments as they happen. Notifications for Context Therapeutics highlight significant technical and fundamental shifts that may signal emerging risks. Each alert is generated from real-time data feeds monitoring Context Therapeutics price action and volume.

Price Density Drivers

Context Therapeutics Fundamentals Growth